## Rune Kroken

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2827472/publications.pdf

Version: 2024-02-01

93 1,801 25 38 g-index

97 97 97 97 2716

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Lower circulating neuron-specific enolase concentrations in adults and adolescents with severe mental illness. Psychological Medicine, 2023, 53, 1479-1488.	4.5	6
2	Neural Activation in the Ventromedial Prefrontal Cortex Precedes Conscious Experience of Being in or out of a Transient Hallucinatory State. Schizophrenia Bulletin, 2023, 49, S58-S67.	4.3	7
3	Plasma Levels of the Cytokines B Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) in Schizophrenia, Bipolar, and Major Depressive Disorder: A Cross Sectional, Multisite Study. Schizophrenia Bulletin, 2022, 48, 37-46.	4.3	10
4	Increased circulating IL-18 levels in severe mental disorders indicate systemic inflammasome activation. Brain, Behavior, and Immunity, 2022, 99, 299-306.	4.1	33
5	Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia. Journal of Clinical Psychopharmacology, 2022, 42, 37-42.	1.4	8
6	Association between C-reactive protein levels and antipsychotic treatment during 12Âmonths follow-up period after acute psychosis. Schizophrenia Research, 2022, 241, 174-183.	2.0	3
7	Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. Acta Neuropsychiatrica, 2022, 34, 282-288.	2.1	2
8	Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness. World Journal of Psychiatry, 2022, 12, 521-532.	2.7	1
9	Negative valence of hallucinatory voices as predictor of cortical glutamatergic metabolite levels in schizophrenia patients. Brain and Behavior, 2022, 12, e32446.	2.2	3
10	Illicit substances detected through high-resolution MS analysis in urine samples are associated with greater symptom burden in patients with psychosis. Emerging Trends in Drugs, Addictions, and Health, 2021, 1, 100024.	1.1	0
11	Pragmatic antipsychotics trialâ€"caution in interpretation â€" Authors' reply. Lancet Psychiatry,the, 2021, 8, 101.	7.4	1
12	Glutamate- and GABA-Modulated Connectivity in Auditory Hallucinations—A Combined Resting State fMRI and MR Spectroscopy Study. Frontiers in Psychiatry, 2021, 12, 643564.	2.6	7
13	Differential Effectiveness of Atypical Antipsychotics on Hallucinations. Journal of Clinical Psychopharmacology, 2021, Publish Ahead of Print, 389-396.	1.4	2
14	The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis. Substance Use and Misuse, 2021, 56, 1880-1891.	1.4	0
15	Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study. NPJ Schizophrenia, 2021, 7, 39.	3.6	35
16	Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: A prospective total-cohort study. Schizophrenia Research, 2021, 235, 29-35.	2.0	12
17	Cognitive change and antipsychotic medications: Results from a pragmatic rater-blind RCT. Schizophrenia Research: Cognition, 2021, 26, 100204.	1.3	2
18	White Matter Microstructural Differences between Hallucinating and Non-Hallucinating Schizophrenia Spectrum Patients. Diagnostics, 2021, 11, 139.	2.6	6

#	Article	IF	Citations
19	The association between cytokines and psychomotor speed in a spectrum of psychotic disorders: A longitudinal study. Brain, Behavior, & Immunity - Health, 2021, 18, 100392.	2.5	6
20	Intra-Regional Glu-GABA vs Inter-Regional Glu-Glu Imbalance: A 1H-MRS Study of the Neurochemistry of Auditory Verbal Hallucinations in Schizophrenia. Schizophrenia Bulletin, 2020, 46, 633-642.	4.3	23
21	T16. SCHIZOPHRENIA SPECTRUM DISORDER: DEPRESSION TRAJECTORIES AND IMMUNE MARKERS. Schizophrenia Bulletin, 2020, 46, S237-S237.	4.3	0
22	T206. ANTIPSYCHOTIC EFFECTIVENESS FOCUSING ON INSIGHT. Schizophrenia Bulletin, 2020, 46, S310-S311.	4.3	0
23	M41. TRAJECTORIES AND PREDICTORS OF OUTCOME IN SCHIZOPHRENIA: THE BENEFICIAL ROLE OF AMISULPRIDE. Schizophrenia Bulletin, 2020, 46, S149-S150.	4.3	0
24	M47. AKATHISIA AND ATYPICAL ANTIPSYCHOTICS: EXPLORING ASSOCIATIONS TO SUICIDALITY AND AGITATION. Schizophrenia Bulletin, 2020, 46, S151-S152.	4.3	2
25	M146. NEUROCHEMICAL MODULATION OF AUDITORY CORTEX FUNCTIONAL CONNECTIVITY IN PATIENTS WITH AUDITORY VERBAL HALLUCINATIONS. Schizophrenia Bulletin, 2020, 46, S191-S191.	4.3	0
26	Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1095-1103.	1.5	28
27	Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt) Tj ETQq $1\ 1\ 0.7$	84314 rgl 7.4	BT <sub>3</sub> /Overloc
28	One-Year Outcome and Adherence to Pharmacological Guidelines in First-Episode Schizophrenia. Journal of Clinical Psychopharmacology, 2020, 40, 534-540.	1.4	10
29	Does childhood trauma influence cognitive functioning in schizophrenia? The association of childhood trauma and cognition in schizophrenia spectrum disorders Schizophrenia Research: Cognition, 2020, 21, 100179.	1.3	14
30	Hallucinating schizophrenia patients have longer left arcuate fasciculus fiber tracks: a DTI tractography study. Psychiatry Research - Neuroimaging, 2020, 302, 111088.	1.8	9
31	Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design. Trials, 2020, 21, 492.	1.6	6
32	Different response patterns in hallucinations and delusions to antipsychotic treatment. Nordic Journal of Psychiatry, 2020, 74, 497-504.	1.3	3
33	Elderly patients with no previous psychiatric history: suicidality and other factors relating to psychiatric acute admissions. BJPsych Open, 2020, 6, e63.	0.7	1
34	Dynamic Functional Connectivity Patterns in Schizophrenia and the Relationship With Hallucinations. Frontiers in Psychiatry, 2020, 11, 227.	2.6	36
35	T134. THE ROLE OF THE DEFAULT MODE NETWORK IN SCHIZOPHRENIA AND AUDITORY VERBAL HALLUCINATIONS – AN INVESTIGATION OF DYNAMIC FMRI RESTING STATE CONNECTIVITY. Schizophrenia Bulletin, 2020, 46, S281-S282.	4.3	1
36	Predictors of treatment satisfaction in antipsychotic-na $\tilde{A}$ -ve and previously medicated patients with acute-phase psychosis. Nordic Journal of Psychiatry, 2019, 73, 349-356.	1.3	3

#	Article	lF	CITATIONS
37	Supported accommodation for people with schizophrenia. Nordic Journal of Psychiatry, 2019, 73, 211-218.	1.3	3
38	Borderline Personality Disorder: What Predicts Acute Psychiatric Readmissions?. Journal of Personality Disorders, 2019, 35, 1-13.	1.4	9
39	Cognitive Profile in Ultra High Risk for Psychosis and Schizophrenia: A Comparison Using Coordinated Norms. Frontiers in Psychiatry, 2019, 10, 695.	2.6	13
40	S2. CHILDHOOD TRAUMA SUBTYPES IN RELATION TO COGNITIVE FUNCTIONING IN SCHIZOPHRENIA SPECTRUM DISORDERS. Schizophrenia Bulletin, 2019, 45, S306-S306.	4.3	0
41	The influence of substance use on the effectiveness of antipsychotic medication: a prospective, pragmatic study. Nordic Journal of Psychiatry, 2019, 73, 281-287.	1.3	6
42	Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. British Journal of Clinical Pharmacology, 2019, 85, 1598-1606.	2.4	38
43	Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis. Acta Neuropsychiatrica, 2019, 31, 36-45.	2.1	15
44	S234. ONE-YEAR OUTCOME AND USE OF CLOZAPINE IN FIRST-EPISODE SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S417-S418.	4.3	0
45	Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. Psychiatry Research, 2018, 261, 481-487.	3.3	20
46	The Beliefs about Voices Questionnaire – Revised: A factor structure from 450 participants. Psychiatry Research, 2018, 259, 95-103.	3.3	19
47	S57. TREATMENT SATISFACTION IN ACUTE PHASE PSYCHOSIS: COMPARISON BETWEEN ANTIPSYCHOTIC NAÃVE AND PREVIOUSLY MEDICATED PATIENTS. Schizophrenia Bulletin, 2018, 44, S346-S346.	4.3	O
48	S87. THE INITIAL CHANGE IN THE SERUM LEVEL OF C-REACTIVE PROTEIN IN ACUTE PSYCHOSIS IS ASSOCIATED WITH COGNITIVE PERFORMANCE IN LATER PHASES. Schizophrenia Bulletin, 2018, 44, S358-S359.	4.3	0
49	S3. CHILDHOOD TRAUMA AND COGNITIVE FUNCTIONING IN SCHIZOPHRENIA SPECTRUM DISORDERS: EFFECT OF FREQUENCY AND TYPE OF CHILDHOOD TRAUMA. Schizophrenia Bulletin, 2018, 44, S324-S325.	4.3	O
50	Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. NPJ Schizophrenia, 2018, 4, 22.	3.6	53
51	Trajectories of depressive symptoms in the acute phase of psychosis: Implications for treatment. Journal of Psychiatric Research, 2018, 103, 219-228.	3.1	6
52	Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics. Frontiers in Psychiatry, 2018, 9, 753.	2.6	58
53	Childhood trauma in schizophrenia spectrum disorder as compared to other mental health disorders. Psychosis, 2017, 9, 48-56.	0.8	17
54	The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry, 2016, 16, 60.	2.6	54

#	Article	IF	CITATIONS
55	Patient satisfaction after acute admission for psychosis. Nordic Journal of Psychiatry, 2016, 70, 321-328.	1.3	23
56	Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample ( $N=1119$ ). Schizophrenia Research, 2016, 170, 217-221.	2.0	47
57	The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement. PLoS ONE, 2016, 11, e0167390.	2.5	18
58	Influence of different second generation antipsychotics on the QTc interval: A pragmatic study. World Journal of Psychiatry, 2016, 6, 442.	2.7	11
59	Borderline Personality Disorder and Posttraumatic Stress Disorder at Psychiatric Discharge Predict General Hospital Admission for Selfâ€Harm. Journal of Traumatic Stress, 2015, 28, 556-562.	1.8	14
60	Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: A 1H MRS study. Schizophrenia Research, 2015, 161, 252-260.	2.0	55
61	Suicidality in Schizophrenia Spectrum Disorders: The Relationship to Hallucinations and Persecutory Delusions. European Psychiatry, 2015, 30, 830-836.	0.2	77
62	Auditory verbal hallucinations reflect stable auditory attention deficits: a prospective study. Cognitive Neuropsychiatry, 2015, 20, 81-94.	1.3	16
63	A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation. Frontiers in Psychiatry, 2014, 5, 11.	2.6	35
64	Cognitive changes in patients with acute phase psychosisâ€"Effects of illicit drug use. Psychiatry Research, 2014, 220, 818-824.	3.3	9
65	The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Frontiers in Psychiatry, 2014, 5, 159.	2.6	30
66	Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia. NeuroImage: Clinical, 2014, 4, 576-584.	2.7	53
67	Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies. Therapeutic Advances in Psychopharmacology, 2014, 4, 228-239.	2.7	18
68	Self-harm induced somatic admission after discharge from psychiatric hospital – a prospective cohort study. European Psychiatry, 2014, 29, 246-252.	0.2	18
69	Failure of attention focus and cognitive control in schizophrenia patients with auditory verbal hallucinations: Evidence from dichotic listening. Schizophrenia Research, 2013, 147, 301-309.	2.0	47
70	Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. BMC Psychiatry, 2013, 13, 241.	2.6	10
71	Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial. European Psychiatry, 2013, 28, 174-184.	0.2	21
72	Prospective and concurrent correlates of emotion perception in psychotic disorders: A naturalistic, longitudinal study of neurocognition, affective blunting and avolition. Scandinavian Journal of Psychology, 2013, 54, 261-266.	1.5	0

#	Article	IF	Citations
73	QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics. Schizophrenia Research and Treatment, 2013, 2013, 1-7.	1.5	7
74	Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research. Expert Review of Neurotherapeutics, 2013, 13, 23-36.	2.8	9
75	Dichotic listening, executive functions and grey matter cortical volume in patients with schizophrenia and healthy controls. Scandinavian Journal of Psychology, 2013, 54, 443-450.	1.5	7
76	The role of the primary auditory cortex in the neural mechanism of auditory verbal hallucinations. Frontiers in Human Neuroscience, 2013, 7, 144.	2.0	45
77	Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness. Therapeutic Advances in Chronic Disease, 2012, 3, 287-300.	2.5	11
78	Priapism in Antipsychotic Drug Use: A Rare but Important Side Effect. Case Reports in Psychiatry, 2012, 2012, 1-4.	0.5	13
79	Time-dependent effect analysis of antipsychotic treatment in a naturalistic cohort study of patients with schizophrenia. European Psychiatry, 2012, 27, 489-495.	0.2	10
80	Auditory verbal hallucinations in schizophrenia as aberrant lateralized speech perception: Evidence from dichotic listening. Schizophrenia Research, 2012, 140, 59-64.	2.0	53
81	An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use. Frontiers in Psychiatry, 2012, 3, 94.	2.6	20
82	Patients with Schizophrenia Fail to Up-Regulate Task-Positive and Down-Regulate Task-Negative Brain Networks: An fMRI Study Using an ICA Analysis Approach. Frontiers in Human Neuroscience, 2012, 6, 149.	2.0	36
83	Is Rational Antipsychotic Polytherapy Feasible? A Selective Review. Current Psychiatry Reports, 2012, 14, 244-251.	4.5	11
84	Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry, $2011,11,145.$	2.6	26
85	Sexual Dysfunction and Hyperprolactinemia in Male Psychotic Inpatients: A Cross-Sectional Study. Advances in Urology, 2011, 2011, 1-6.	1.3	11
86	Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study. Nordic Journal of Psychiatry, 2011, 65, 192-202.	1.3	7
87	Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry, 2010, 10, 26.	2.6	53
88	Suicide Risk and Acute Psychiatric Readmissions: A Prospective Cohort Study. Psychiatric Services, 2010, 61, 25-31.	2.0	53
89	Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry, 2009, 9, 24.	2.6	119
90	Enduring cognitive dysfunction in unipolar major depression: A test–retest study using the Stroop paradigm. Scandinavian Journal of Psychology, 2009, 51, 304-8.	1.5	51

## Rune Kroken

#	Article	IF	CITATIONS
91	Antipsychotic-Induced Hyperprolactinemia. Journal of Clinical Psychopharmacology, 2008, 28, 686-690.	1.4	41
92	A longitudinal analysis of neurocognitive function in unipolar depression. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 879-891.	1.3	75
93	"Normalization―of brain activation in schizophrenia. An fMRI study. Schizophrenia Research, 2002, 58, 333-335.	2.0	11